Imunon, Inc. (NASDAQ:IMNN) Stock Short Interest Report for October

Imunon, Inc. (NASDAQ:IMNN) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 215,645 shares, a growth of 245.8% from the October 15th total of 62,366 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average daily volume of 144,672 shares, the short-interest ratio is currently 1.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Stock Down 11.6%

NASDAQ IMNN traded down $0.08 on Thursday, reaching $0.64. The company had a trading volume of 2,183,534 shares, compared to its average volume of 111,021. The company has a quick ratio of 1.82, a current ratio of 1.82 and a debt-to-equity ratio of 2.86. The company’s fifty day moving average is $1.19 and its 200 day moving average is $2.14. Imunon has a 52-week low of $0.49 and a 52-week high of $4.38. The stock has a market capitalization of $3.57 million, a P/E ratio of -0.17 and a beta of 2.10.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). Sell-side analysts anticipate that Imunon will post -2.68 earnings per share for the current fiscal year.

Imunon Company Profile

Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells. Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.